Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
about
Biology of RANK, RANKL, and osteoprotegerinVascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfateA review of UHMWPE wear-induced osteolysis: the role for early detection of the immune response.Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseOsteoprotegerin rich tumor microenvironment: implications in breast cancerHypercalcemia of Malignancy: An Update on Pathogenesis and ManagementRisk factors for osteoporosis in inflammatory bowel disease patientsMechanisms of ectopic calcification: implications for diabetic vasculopathyThe role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosisBiomaterial delivery of morphogens to mimic the natural healing cascade in boneBone health and associated metabolic complications in neuromuscular diseasesLocomotive syndrome is associated with body composition and cardiometabolic disorders in elderly Japanese womenOsteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular diseaseRelationship between serum RANKL and RANKL in bonePulsed electromagnetic fields improve bone microstructure and strength in ovariectomized rats through a Wnt/Lrp5/β-catenin signaling-associated mechanismMetabolomic profiles delineate signature metabolic shifts during estrogen deficiency-induced bone loss in rat by GC-TOF/MSEssential role of beta-catenin in postnatal bone acquisitionTargeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasisAssociation of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.A physical mechanism for coupling bone resorption and formation in adult human bone.A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer.Osteoporosis: the current status of mesenchymal stem cell-based therapy.Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosisMolecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis.Pharmacological management of osteogenesis.Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo.Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potentialCurrent developments in salivary diagnostics.Role of bone mineral density in the inverse relationship between body size and aortic calcification: results from the Baltimore Longitudinal Study of AgingCirculating osteoprotegerin is associated with chronic kidney disease in hypertensive patientsMicrofibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling.TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women.Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritisSubchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis.Pathophysiology of Bone Remodelling and Current Therapeutic Approaches.Osteoprotegerin as a marker of atherosclerosis: a systematic update.The association between metabolic syndrome and bone mineral density: a meta-analysis.
P2860
Q21195419-48A936F9-5A30-4AF3-8918-C0562D0EB467Q24795302-E86F7904-4C72-4776-84BE-83BFEADA8FCEQ26741081-06661457-277C-4694-B27E-24C97F14B80EQ26747224-EEAFBDEA-4DA2-48DE-B7D6-D653C86AF3DEQ26748804-F74F6DF3-E101-4870-9BE7-91EC243834EEQ26771719-16243396-5337-4C0D-A450-5F990AA38F76Q26776142-3FEFDE1F-0D60-4646-B3C4-B2F67FE1506FQ26778664-B17DCEEF-B12F-4CF5-8795-56E0A1DABF26Q26780523-05994C1D-EA69-406C-A159-9091F0F5D508Q26996479-665788A7-B501-4630-A083-E1C71E781B0DQ27025688-CC93630F-D59B-4E54-910B-5762910C83CBQ27312481-B529DA9D-7F86-4E3F-A263-163A899C3530Q27692635-F8E5F01D-9050-4C70-9081-2DF48D9E8F03Q28076305-347BF946-0089-4BEB-8F47-2D3EC86B0DA0Q28245828-6F85FF0F-E8B2-4DB1-AC85-CEF198F605A7Q28302165-9880F879-9AA0-4D05-AFC3-6C9584D73D65Q28486063-418B6CB1-AC64-4062-829D-99FFBCAAB5C6Q28594492-18388F39-7FB9-4514-9D65-8C389641AA1DQ28731449-7CFE9B55-CBE3-4737-B8DD-27E76A79D356Q30477731-FF197433-1C6F-421A-9857-788A3145AC24Q30485638-FBBAF4D1-0D2B-4121-B49D-2C8B8E9A1F41Q33358300-34A26BEC-A506-4CFE-9B4E-B78BB21418CAQ33631498-836DF316-DDEF-4629-8292-03C83ABC8DBFQ33663460-B46391E3-2185-4BD4-B058-758B3D5BEBA8Q33712272-41BE7B61-CF6F-4667-A3A9-CE36EF0053B6Q33729548-6CF0F019-6BF5-4EED-9F26-6D321358CC6FQ33754036-F0F8B51F-1956-4B62-A4CD-63EBC6DA5463Q33779634-621D3CAF-2F8B-4A99-9B7C-510C290986E9Q33788192-6C5BD535-FE69-4FC4-A666-EE667B67F9C6Q33795328-7C8488A6-6B45-4FB9-A9B5-DBA2911BAD1FQ33803001-D709F66B-1734-48F2-81D3-8F2694245D32Q33840740-4EC641AC-E14A-4297-8212-4B9B83953DA3Q33882341-C03D9FB0-905A-45B6-B4FE-C82734A89242Q34025344-B2EF117E-652D-4F9C-B136-D3F47B31EF81Q34126306-96DBAFA9-023C-4B35-ACCB-606CA3095300Q34128912-D89E885E-A19D-4097-ABB0-5CE59657B8AAQ34153080-4FC69A0E-AE94-45FF-8959-2A690143CA1EQ34209614-E79F372C-983A-4CB9-8797-EC840697E0EFQ34234163-AF53B4AE-8D21-4D76-8A48-FB83AA302456Q34252441-68B012CE-5DAB-416B-A3E3-9F49EE16FF89
P2860
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical implications of the o ...... or bone and vascular diseases.
@ast
Clinical implications of the o ...... or bone and vascular diseases.
@en
type
label
Clinical implications of the o ...... or bone and vascular diseases.
@ast
Clinical implications of the o ...... or bone and vascular diseases.
@en
prefLabel
Clinical implications of the o ...... or bone and vascular diseases.
@ast
Clinical implications of the o ...... or bone and vascular diseases.
@en
P356
P1476
Clinical implications of the o ...... for bone and vascular diseases
@en
P2093
Michael Schoppet
P304
P356
10.1001/JAMA.292.4.490
P407
P577
2004-07-01T00:00:00Z